Laurent Beaugerie1, Fabrice Carrat2, Jean-Frédéric Colombel3, Anne-Marie Bouvier4, Harry Sokol1, Abdenour Babouri5, Franck Carbonnel6, David Laharie7, Jean-Luc Faucheron8, Tabassome Simon9, Aimery de Gramont10, Laurent Peyrin-Biroulet5. 1. Department of Gastroenterology, AP-HP, Hôpital Saint-Antoine F-75012; ERL 1057 INSERM/UMRS 7203; GRC-UPMC 03, UPMC Univ Paris 06 F-75012, Paris, France. 2. Department of Public Health, Hôpital Saint-Antoine, AP-HP, F-75012 and UMR-S 707, INSERM & UPMC Univ Paris 06 F-75012, Paris, France. 3. Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 4. Registre Bourguignon des Cancers Digestifs F-21079; Inserm U866; CHRU Dijon; Université de Bourgogne, Dijon, France. 5. Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, Université Henri Poincaré 1, Vandoeuvre-lès-Nancy, Nancy, France. 6. Department of Gastroenterology, Assistance Publique-Hôpitaux de Paris (AP-HP), University hospitals Paris-Sud, Site de Bicêtre, Paris Sud University, Paris XI, Le Kremlin Bicêtre, Villejuif, France. 7. CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie-Univ. Bordeaux, Laboratoire de bactériologie, F-33000 Bordeaux, Pessac, France. 8. Colorectal Unit, Department of Surgery, Grenoble University Hospital, CS 10217, 38043 Grenoble cedex, Grenoble, France. 9. Clinical Pharmacology Unit, Unité de Recherche clinique de l'Est Parisien, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, F-75012; UPMC Univ Paris 06, Paris, France. 10. Department of Oncology, AP-HP, Hôpital Saint-Antoine F-75012, Paris, France.
Abstract
OBJECTIVE: To explore the risk of new or recurrent cancer among patients with IBD and previous cancer, exposed or not to immunosuppressants. DESIGN: Among the 17 047 patients of the CESAME prospective observational cohort who were enrolled from May 2004 to June 2005, and followed-up until December 2007, we identified 405 patients with cancer diagnosed previous to study entry. We calculated the rates of incident cancer in patients with or without previous cancer, and we assessed by survival analysis and nested case-control study the impact of immunosuppressants on the risk of incident new or recurrent cancer in patients with previous cancer. RESULTS: The rate of incident cancer was 21.1/1000 patient-years (PY) and 6.1/1000 PY in patients with and without previous cancer, respectively. The multivariate-adjusted HR of incident cancer between patients with and without previous cancer was 1.9 (95% CI 1.2 to 3.0, p=0.003). Among patients with previous cancer, the rates of new and recurrent cancers were, respectively, 13.2/1000 PY and 6.0/1000 PY in the 312 patients who were not taking immunosuppressant at the time of study entry, and 23.1/1000 PY and 3.9/1000 PY in the 93 patients treated with immunosuppressants at study entry. There was no significant association between the exposure to immunosuppressants and the risk of new or recurrent cancer. CONCLUSIONS: Patients with IBD with a history of cancer are at increased risk of developing any (new or recurrent) cancer, with a predominant incidence of new cancers. Treatment with immunosuppressants has no overall major impact per se on this risk. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To explore the risk of new or recurrent cancer among patients with IBD and previous cancer, exposed or not to immunosuppressants. DESIGN: Among the 17 047 patients of the CESAME prospective observational cohort who were enrolled from May 2004 to June 2005, and followed-up until December 2007, we identified 405 patients with cancer diagnosed previous to study entry. We calculated the rates of incident cancer in patients with or without previous cancer, and we assessed by survival analysis and nested case-control study the impact of immunosuppressants on the risk of incident new or recurrent cancer in patients with previous cancer. RESULTS: The rate of incident cancer was 21.1/1000 patient-years (PY) and 6.1/1000 PY in patients with and without previous cancer, respectively. The multivariate-adjusted HR of incident cancer between patients with and without previous cancer was 1.9 (95% CI 1.2 to 3.0, p=0.003). Among patients with previous cancer, the rates of new and recurrent cancers were, respectively, 13.2/1000 PY and 6.0/1000 PY in the 312 patients who were not taking immunosuppressant at the time of study entry, and 23.1/1000 PY and 3.9/1000 PY in the 93 patients treated with immunosuppressants at study entry. There was no significant association between the exposure to immunosuppressants and the risk of new or recurrent cancer. CONCLUSIONS:Patients with IBD with a history of cancer are at increased risk of developing any (new or recurrent) cancer, with a predominant incidence of new cancers. Treatment with immunosuppressants has no overall major impact per se on this risk. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Azathioprine; Cancer Epidemiology; Crohn's Disease; Ulcerative Colitis
Authors: Frank I Scott; Ronac Mamtani; Colleen M Brensinger; Kevin Haynes; Zelma C Chiesa-Fuxench; Jie Zhang; Lang Chen; Fenglong Xie; Huifeng Yun; Mark T Osterman; Timothy Beukelman; David J Margolis; Jeffrey R Curtis; James D Lewis Journal: JAMA Dermatol Date: 2016-02 Impact factor: 10.282
Authors: Joseph Meserve; Satimai Aniwan; Jenna L Koliani-Pace; Preeti Shashi; Aaron Weiss; David Faleck; Adam Winters; Shreva Chablaney; Gursimran Kochhar; Brigid S Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Justin G Hartke; Prianka Chilukuri; Matthew Bohm; Sashidhar Varma Sagi; Monika Fischer; Dana Lukin; David Hudesman; Shannon Chang; Youran Gao; Keith Sultan; Arun Swaminath; Nitin Gupta; Sunanda Kane; Edward V Loftus; Bo Shen; Bruce E Sands; Jean-Frederic Colombel; Corey A Siegel; William J Sandborn; Parambir S Dulai Journal: Clin Gastroenterol Hepatol Date: 2018-09-27 Impact factor: 11.382
Authors: Ronac Mamtani; Amy S Clark; Frank I Scott; Colleen M Brensinger; Ben Boursi; Lang Chen; Fenglong Xie; Huifeng Yun; Mark T Osterman; Jeffrey R Curtis; James D Lewis Journal: Arthritis Rheumatol Date: 2016-10 Impact factor: 10.995